Terrific talk from Dr. @SighPichamol on where endo-hepatology meets bariatric endoscopy for MASLD/MASH • One EUS session = shear-wave elastography portal pressure gradient liver biopsy • Endoscopic gastric remodeling lifestyle delayed major adverse liver outcomes in MASH cirrhosis (p=0.02) • EGR GLP-1RA beat EGR alone: 18.2% vs 9.6% TWL & greater fibrosis reduction • A practical algorithm to fold endo-hepatology into a bariatric practice Treating the weight and the liver together. Look forward to attending again next year. Thanks Drs. @PeterLee1209 & @Jarshah4 @BrighamGI #MASLD #MASH #EndoHepatology #BariatricEndoscopy

Einstein challenged what people thought was possible. I’m challenging what people thought was impossible. #MASLD #Cirrhosis #FattyLiver #LiverHealth #LiverDoc

They said advanced cirrhosis was irreversible. 65.8 kPa (Acute Liver Crisis & Advanced Cirrhosis) ↓ 205 Days 16.1 kPa (Documented Regression in Liver Stiffness) You’re not the true King of the Liver until you’ve conquered the liver. MASLD 5-Pillar System™

Gut #microbiota–derived indole-3-propionic acid alleviates endoplasmic reticulum stress by regulating FMO2 in #MASLD @HepCommJournal journals.lww.com/hepcomm/ful…

Vitamin E dosing study in patients with #MASLD. journals.lww.com/hep/abstrac…

RT @novonordisk: How can primary care detect metabolic dysfunction–associated steatotic liver disease (MASLD) earlier before it progresses…

RT @novonordisk: How can multidisciplinary collaboration improve the management of MASLD and MASH across specialties? This expert-led serie…

Por la sensibilidad a la insulina, el bueno será retatutrida, actúa directamente en el hígado. Los efectos hepáticos de semaglutida se atribuyen principalmente a mejora sistémica (reducción de glucosa, insulina, peso). GcgR es el que tiene mayor expresión. El glucagón actúa directamente sobre hepatocitos promoviendo glucogenólisis, gluconeogénesis y β-oxidación de ácidos grasos. Este receptor es precisamente una razón por la que retatrutida tiene efectos más marcados en reducción de grasa hepática (MASLD/MASH). Tirzepatida, con GIP tiene expresión hepática documentada; contribuye a regulación de lípidos y metabolismo energético.

Lean MASLD: for better or worse? Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global cause of chronic liver disease, affecting both obese and lean individuals. In a large study of 186,221 participants across three cohorts with 14-year follow-up, lean MASLD was linked to worse outcomes than non-lean MASLD. It showed higher risks of liver-related events, liver-related mortality, and all-cause mortality, despite similar cancer risk and lower cardiovascular disease incidence. These findings highlight a distinct risk profile, suggesting BMI alone is insufficient for assessment and emphasizing the need for tailored management and further research. ⚖️ Has lean MASLD been wrongly risk stratified in clinical practice? 🔎 Check out the the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" via bit.ly/3Rf2yO8 Social Media summary by Dr David Gomez, ST4 Gastroenterology, Royal Free London NHS Foundation Trust, London, UK @DrDAGomez

Lean MASLD: for better or worse? Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global cause of chronic liver disease, affecting both obese and lean individuals. In a large study of 186,221 participants across three cohorts with 14-year follow-up, lean MASLD was linked to worse outcomes than non-lean MASLD. It showed higher risks of liver-related events, liver-related mortality, and all-cause mortality, despite similar cancer risk and lower cardiovascular disease incidence. These findings highlight a distinct risk profile, suggesting BMI alone is insufficient for assessment and emphasizing the need for tailored management and further research. ⚖️ Has lean MASLD been wrongly risk stratified in clinical practice? 🔎 Check out the the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" via bit.ly/3Rf2yO8 Social Media summary by Dr David Gomez, ST4 Gastroenterology, Royal Free London NHS Foundation Trust, London, UK @DrDAGomez

Tras el día mundial #MASLD, mostramos el último estudio del Registro Hepamet en @AGA_CGH Con la llegada de las nuevas terapias, ¿podemos seleccionar correctamente a los candidatos a tratamiento (F2-F3)? 🚨Estudio de 1281 pacientes con MASLD biopsiados. pubmed.ncbi.nlm.nih.gov/4090…

Following #MASLD Day, we share the latest study from HEPAmet Registry, published in @AGA_CGH With the arrival of new therapies, the question is: Can we identify patients who are candidates for treatment (F2–F3)? 🚨1281 patients with biopsy-proven MASLD pubmed.ncbi.nlm.nih.gov/4090…

EPISODE 149: GLP-1 drugs are excellent for treating weight loss, diabetes & dangerous fatty liver disease. Clinical trials of #SURVODUTIDE, a new GLP-1 & Glucagon receptor agonist may be best for fatty liver. Watch expert physician @Carel_LeRoux to learn future of these drugs. 0:00 - Introduction & Guest Overview 0:34 - Episode Welcome: Dr. Robert Cykiert 0:48 - Entering Dublin: The GLP-1 Breakthrough 2:27 - Long-Term Health Hazards of Obesity & Diabetes 3:24 - Why Obesity is a Disease of the Brain, Not Willpower 4:57 - Ozempic (Semaglutide) vs. Mounjaro (Tirzepatide) 6:16 - The Fatty Liver Disease (MASLD/MASH) Epidemic 7:50 - The Truth About Visceral vs. Ectopic Fat 10:04 - Survodutide Explained: The New Dual Agonist 12:45 - Managing Side Effects & Titration Schedules 15:37 - Boehringer Ingelheim & the Future of Obesity Medicine 16:48 - Retatrutide: Eli Lilly’s New Triple Agonist 18:26 - A 30-Second Guide for Doctors & Patients 20:11 - Closing Thoughts & Patient Transformations